Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Biologics

Plan Ahead: Clinical Tips for Managing Reproductive Health in Patients with Rheumatic Disease

Jason Liebowitz, MD, FACR  |  September 24, 2024

Dr. May Ching Soh highlighted practical approaches when caring for pregnant patients with rheumatic disease.

Filed under:ConditionsMeeting Reports Tagged with:APLARAPLAR 2024Asia Pacific League of Associations for Rheumatology (APLAR)pregnancypregnancy complicationspregnant women

How the ACR Helps with Reimbursement, Utilization Management & Other Practice Challenges

Carina Stanton  |  September 6, 2024

Improving reimbursement for underwater biosimilars is just one example of how the ACR’s practice advocates have achieved solutions to members’ insurance challenges. Here’s a look at current ACR efforts in insurance advocacy and how to get help with your own insurance challenges.

Filed under:InsurancePractice ManagementPractice Support Tagged with:ACR advocacyACR Insurance Subcommittee (ISC)Member benefits

ACR Comments on 2025 Physician Fee Schedule

From the College  |  September 6, 2024

The ACR’s response to the Centers for Medicare & Medicaid Services addresses the likely harm of the proposed conversion factor on the solvency and stability of rheumatology practices. The comments also include recommendations on complex drug administration coding, inflation-adjusted drug rebates and extending telehealth flexibilities.

Filed under:From the CollegeLegislation & Advocacy Tagged with:ACR advocacyMedicare Physician Fee Schedule (MPFS)

Draft FDA Guidance No Longer Requires Biosimilar Switching Studies

From the College  |  August 17, 2024

The updated draft guidance, released in June, would accept an assessment of why data provided meet the switching standard to demonstrate interchangeability of biosimilars

Filed under:GuidanceLegislation & Advocacy Tagged with:Biosimilarsinterchangeability

FDA Approves 2 Upadacitinib Formulations for Children with pJIA & PsA

Michele B. Kaufman, PharmD, BCGP  |  August 13, 2024

Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:FDAFDA approvalpJIApolyarticular juvenile idiopathic arthritis (JIA)PsAPsA Resource CenterPsoriatic ArthritisU.S. Food and Drug Administration (FDA)upadacitinib

Summary of Notable Provisions in CY 2025 Medicare PFS Proposed Rule

From the College  |  July 19, 2024

The ACR will provide comments on several provisions related to Medicare physician payment and the Quality Payment Program.

Filed under:Legislation & AdvocacyPractice Support Tagged with:Medicare Physician Fee Schedule (MPFS)Medicare ReimbursementQuality Payment Program (QPP)

CAR-T Cell Therapy in Autoimmune Disease: The Next Frontier

Jason Liebowitz, MD, FACR  |  July 2, 2024

Chimeric antigen receptor (CAR) T cell therapy has the potential to fundamentally shift the treatment of autoimmune disease. During his presentation at EULAR 2024, Georg Schett, MD, provided an overview of this treatment process and described the promising findings of the latest research.

Filed under:Biologics/DMARDsConditionsEULAR/OtherMeeting ReportsSystemic Lupus Erythematosus Tagged with:CAR-T cell therapychimeric antigen receptor T (CAR-T) cellsEULAR 2024ImmunologyResearchSLE Resource Centersystemic lupus erythematosus (SLE)

ACR Successfully Leads Coalition in AMA House of Delegates to Support Higher Pediatric Specialist Compensation

From the College  |  June 25, 2024

An ACR-led resolution that calls for Medicaid payment parity for pediatric specialists will become AMA policy.

Filed under:From the CollegeLegislation & Advocacy Tagged with:AMA House of Delegates (HOD)Medicare ReimbursementPediatric Rheumatology

Pharmacy Benefit Managers Under Scrutiny

Elizabeth Hofheinz, MPH, MEd  |  June 10, 2024

“When pharmacy benefit managers [PBMs] came into being 30 years ago, they were seen as an important component of the prescription distribution system [because] they could guide benefits and money between the patient, pharmacy and the manufacturer,” says Angus Worthing, MD, president of the Alliance for Transparent & Affordable Prescriptions (ATAP). Health insurance companies hire…

Filed under:Drug UpdatesLegislation & Advocacy Tagged with:drug pricingdrug pricing transparencypharmacy benefit managers (PBMs)

How to Effectively Diagnose & Treat Macrophage Activation Syndrome

Vanessa Caceres  |  May 30, 2024

“As a resident, [I] felt pretty terrible when [we had] a very sick child and the teams [couldn’t] agree on what to do,” said Lauren Henderson, MD, MMS, on an episode of ACR on Air. She discussed the importance of collaboration across specialties in the identification and treatment of macrophage activation syndrome (MAS).

Filed under:ConditionsPediatric ConditionsVasculitis Tagged with:hemophagocytic lymphohistiocytosis (HLH)macrophage activation syndromeMASpatient care

  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 75
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences